Cardiac safety testing is an important part of the approval of new chemical entities (NCEs). For more than 20 years, cardiac safety testing has been focused on QT interval assessment as a surrogate for the potential of an NCE to cause “Torsade de Pointes” — a specific life-threatening ventricular arrhythmia that is potentially associated with QT interval prolongation. However, these analyses have been conducted using limited, short-term data in a resting state.
Newer technologies allow for the collection of long-term data in a more dynamic, real-world setting. Cardiac monitoring has benefited from the advent of multiple-day recordings, allowing for ECG collection in dynamic settings.
Regulatory agencies are becoming more aware of the need to gather long-term cardiovascular data, and the new technologies available to facilitate collection. As long-term cardiovascular technology advances, it will become increasingly easier to utilise it for the collection of continuous cardiovascular safety data in clinical trials.
In this webinar, the expert speaker will discuss:
The basics of long-term cardiac monitoring
What the technology entails
How and when to deploy the technology
What data are collected
How the data are analysed
Register for this webinar today to gain insights into the transformative impact of long-term cardiovascular monitoring technologies on clinical trials.
Keywords: Cardiovascular Disease, Drug Development, Clinical Research, CRO, Cardiovascular, Pharmacovigilance, Cardiovascular Health, Clinical Data, Therapeutic Areas, Cardiology, Cardiac Safety, Cardiovascular Clinical Trials